Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/tazobactam for CF and Bronchiectasis Exacerbations
NCT06035055Phase 4Unknown
- Sponsor
- Sunshine Coast Hospital and Health Service
- Start
- Oct 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of ceftolozane + tazobactam in cystic fibrosis (CF) and bronchiectasis, sponsored by Sunshine Coast Hospital and Health Service. Primary endpoint: Feasibility of ceftolozane/tazobactam continuous infusion in OPAT at Day 90. Status: unknown.
02
Drugs
ceftolozane + tazobactam
03
Conditions
cystic fibrosis (CF)bronchiectasis
Beyond the preview
Go deeper on NCT06035055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035055.